Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Pentoxifylline adjunct to risperidone for negative symptoms of stable schizophrenia: A randomized, double-blind, placebo-controlled trial.
Int J Neuropsychopharmacol
December 2024
Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Background: Negative symptoms of schizophrenia represent an unmet therapeutic need for many patients on whom pentoxifylline may be effective in terms of its dopaminergic, anti-inflammatory, and cerebral blood flow-increasing properties. This study aimed to evaluate pentoxifylline as a therapeutic agent for improving negative symptoms of schizophrenia.
Methods: Chronic schizophrenia outpatients experiencing significant negative symptoms were randomly allocated to receive pentoxifylline 400 mg or matched placebo q12hr for eight weeks.
Triangulating evidence from the GALENOS living systematic review on trace amine-associated receptor 1 (TAAR1) agonists in psychosis.
Br J Psychiatry
December 2024
Population Health Sciences, Bristol Medical School, University of Bristol, UK.
Background: Trace amine-associated receptor 1 (TAAR1) agonists offer a new approach, but there is uncertainty regarding their effects, exact mechanism of action and potential role in treating psychosis.
Aims: To evaluate the available evidence on TAAR1 agonists in psychosis, using triangulation of the output of living systematic reviews (LSRs) of animal and human studies, and provide recommendations for future research prioritisation.
Method: This study is part of GALENOS (Global Alliance for Living Evidence on aNxiety, depressiOn and pSychosis).
Navigating agitation in neurodevelopmental disorders: A comparative study of pharmacotherapies via network meta-analysis in children and adults with autism spectrum disorder or intellectual disabilities.
J Psychopharmacol
December 2024
Department of Psychiatry, Queen's University, Kingston, ON, Canada.
Importance: Individuals with autism spectrum disorder (ASD) and intellectual disability often experience persistent challenges related to aggressive behaviour and agitation, highlighting the critical need for evidence-based pharmacological interventions among other strategies. Despite previous network meta-analyses (NMAs), the rapidly evolving landscape of treatment options necessitates ongoing and updated assessments.
Objective: To evaluate the efficacy and tolerability of various pharmacotherapies in managing agitation in children and adults with ASD or intellectual disabilities (ID).
Meta-Analysis of the Efficacy of Risperidone Treatment in Patients with First-Episode Schizophrenia.
Noro Psikiyatr Ars
November 2024
Department of nursing, The First Affiliated Hospital of Hainan Medical College, Hai-kou, China.
Article Synopsis
- First-episode schizophrenia is common and complex, necessitating an evaluation of the treatment effectiveness of risperidone through a meta-analysis of existing studies.
- A total of 15 studies were assessed, showing that risperidone significantly improves cure rates and overall improvement compared to control groups.
- While risperidone is effective, it may cause side effects like weight gain and extrapyramidal symptoms, which need to be considered in treatment plans.
Metformin efficacy and safety as an adjunctive treatment for irritability in children with autism spectrum disorder: A randomized, double-blind, placebo-controlled trial.
J Psychopharmacol
December 2024
Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Background: Antidiabetic medications have shown efficacy in alleviating autism symptoms. However, there is a lack of clinical research on the impact of metformin on irritability associated with autism. This study aimed to assess the efficacy and safety of metformin as an adjuvant therapy with risperidone for managing irritability in children diagnosed with Autism Spectrum Disorder (ASD).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!